Physician profile
Cory J Bosanko
NPI 1730180704
$1,167.69
in general payments reported to CMS, 2019-2025
19 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Low Vision Rehabilitation provider received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $69.82 · 2021: $152 · 2022: $82.15 · 2023: $125 · 2024: $328 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $304.93 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.71 | 2019-2021 | |
| Rxsight INC | $118.08 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $104.96 | 2024 | Xiidra, Miebo |
| Abbvie INC. | $87.13 | 2022-2024 | |
| Dompe US, INC. | $79.13 | 2019-2025 | Oxervate |
| Omeros Corporation | $65.30 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $58.34 | 2024-2025 | Xdemvy |
| Allergan, INC. | $39.68 | 2021 | |
| Harrow Eye, LLC | $28.97 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $28.55 | 2024 | Tyrvaya |
| Horizon Therapeutics Plc | $24.74 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $23.64 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.76 | 2022 | |
| Thea Pharma INC. | $14.69 | 2024 | Iyuzeh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $13.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.07 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $11.89 | 2019 | |
| Biotissue Holdings INC. | $10.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Bosanko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.